LAE-113

N/A

Report date: 2023/11/06 14:34:33

Base Information

Drug NameLAE-113

Drug Alias NameLAE-113

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionNatural killer cells modulatorsTransmembrane protein PVRIG inhibitorsT cell immunoglobulin and ITIM domains inhibitors

TargetsTransmembrane protein PVRIGT cell immunoglobulin and ITIM domains

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLaekna Therapeutics Shanghai Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesLaekna Therapeutics Shanghai Co Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A